Waldron Private Wealth’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$7.37M Sell
29,274
-340
-1% -$73.2K 0.26% 47
2026
Q1
$6.44M Buy
29,614
+541
+2% +$120K 0.25% 46
2025
Q4
$6.64M Buy
29,073
+502
+2% +$114K 0.26% 49
2025
Q3
$6.62M Buy
28,571
+632
+2% +$129K 0.27% 48
2025
Q2
$5.19M Sell
27,939
-216
-0.8% -$40.1K 0.23% 54
2025
Q1
$5.9M Sell
28,155
-9,447
-25% -$1.84M 0.28% 46
2024
Q4
$6.68M Buy
37,602
+3,930
+12% +$723K 0.27% 52
2024
Q3
$6.65M Buy
33,672
+867
+3% +$162K 0.28% 50
2024
Q2
$5.63M Buy
32,805
+115
+0.4% +$19.1K 0.25% 56
2024
Q1
$5.95M Buy
32,690
+1,029
+3% +$177K 0.27% 52
2023
Q4
$4.91M Sell
31,661
-502
-2% -$73.2K 0.23% 55
2023
Q3
$4.79M Buy
32,163
+922
+3% +$135K 0.25% 53
2023
Q2
$4.21M Sell
31,241
-5,772
-16% -$846K 0.21% 60
2023
Q1
$5.9M Buy
37,013
+7,163
+24% +$1.1M 0.29% 50
2022
Q4
$4.01M Hold
29,850
0.25% 63
2022
Q3
$4.01M Buy
29,850
+486
+2% +$69.7K 0.25% 63
2022
Q2
$4.5M Buy
29,364
+1,044
+4% +$160K 0.25% 59
2022
Q1
$4.59M Buy
28,320
+374
+1% +$54.3K 0.24% 65
2021
Q4
$3.78M Buy
27,946
+62
+0.2% +$7.32K 0.19% 77
2021
Q3
$3.01M Buy
27,884
+2,017
+8% +$230K 0.18% 77
2021
Q2
$2.91M Buy
25,867
+117
+0.5% +$13.2K 0.19% 73
2021
Q1
$2.79M Sell
25,750
-109
-0.4% -$11.7K 0.19% 71
2020
Q4
$2.77M Buy
25,859
+657
+3% +$63.1K 0.21% 66
2020
Q3
$2.21M Buy
25,202
+844
+3% +$79.5K 0.19% 72
2020
Q2
$2.39M Sell
24,358
-6,781
-22% -$597K 0.21% 66
2020
Q1
$2.37M Sell
31,139
-1,336
-4% -$114K 0.25% 65
2019
Q4
$2.88M Buy
32,475
+114
+0.4% +$9.46K 0.26% 59
2019
Q3
$2.45M Buy
32,361
+25,204
+352% +$1.73M 0.25% 58
2019
Q2
$520K Sell
7,157
-1,510
-17% -$119K 0.06% 134
2019
Q1
$698K Buy
8,667
+1,745
+25% +$143K 0.08% 115
2018
Q4
$638K Buy
6,922
+1,297
+23% +$114K 0.09% 102
2018
Q3
$532K Buy
5,625
+44
+0.8% +$4.17K 0.1% 96
2018
Q2
$517K Buy
5,581
+41
+0.7% +$4K 0.11% 87
2018
Q1
$524K Hold
5,540
0.12% 80
2017
Q4
$535K Hold
5,540
0.13% 76
2017
Q3
$492K Buy
5,540
+150
+3% +$11.4K 0.14% 74
2017
Q2
$390K Sell
5,390
-1,594
-23% -$107K 0.12% 73
2017
Q1
$446K Buy
6,984
+1,653
+31% +$104K 0.11% 113
2016
Q4
$333K Buy
5,331
+81
+2% +$4.94K 0.11% 83
2016
Q3
$331K Buy
5,250
+115
+2% +$7.45K 0.12% 84
2016
Q2
$317K Sell
5,135
-591
-10% -$36K 0.12% 93
2016
Q1
$327K Buy
5,726
+103
+2% +$5.74K 0.12% 85
2015
Q4
$333K Buy
5,623
+458
+9% +$26.4K 0.12% 96
2015
Q3
$281K Sell
5,165
-843
-14% -$54.9K 0.12% 88
2015
Q2
$403K Sell
6,008
-357
-6% -$23.3K 0.16% 52
2015
Q1
$373K Buy
6,365
+2,595
+69% +$157K 0.15% 56
2014
Q4
$247K Buy
3,770
+17
+0.5% +$1.07K 0.1% 94
2014
Q3
$216K Buy
3,753
+70
+2% +$3.89K 0.1% 100
2014
Q2
$208K Buy
+3,683
New +$193K 0.1% 115

Other funds holding ABBV

Waldron Private Wealth's ABBV Position: Q2 2026 in Review

Waldron Private Wealth reduced its AbbVie (ABBV) stake by 1.1% in Q2 2026, selling an estimated $73.2K and leaving 29,274 shares worth $7.37M. The position accounts for 0.26% of the portfolio, ranked #47.

Waldron Private Wealth first reported a position in ABBV in Q2 2014 and has held it in 49 quarters since. 4,193 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Waldron Private Wealth held 29,274 shares of AbbVie worth $7.37M as of Q2 2026.
  • Waldron Private Wealth sold 340 AbbVie shares in Q2 2026, an estimated $73.2K.
  • AbbVie made up 0.26% of Waldron Private Wealth's portfolio in Q2 2026, its #47 holding.
  • Waldron Private Wealth first reported a position in AbbVie in Q2 2014 and has held it in 49 quarters since.
  • 4,193 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Waldron Private Wealth's 13F filing for Q2 2026, filed 20 Jul 2026.